Best Practice & Research Clinical Haematology
Volume 22, Issue 2 , Pages 249-269 , June 2009

Gene expression changes in normal haematopoietic cells

  • Jack M. Lionberger, MD, PhD (Acting Instructor at the Fred Hutchinson Cancer Research Center and the University of Washington)
    • ,
  • Derek L. Stirewalt, MD (Assistant Member at the Fred Hutchinson Cancer Research Center and Assistant Professor at the University of Washington Medical School)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +1 206 667 5386; Fax: +1 206 667 6519.

References 

  1. Radich JP, Dai H, Mao M, et al. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci U S A. 2006;103:2794–2799
  2. Valk PJ, Verhaak RG, Beijen MA, et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med. 2004;350:1617–1628
  3. Stirewalt DL, Meshinchi S, Kopecky KJ, et al. Identification of genes with abnormal expression changes in acute myeloid leukemia. Genes Chromosomes Cancer. 2008;47:8–20
  4. Robinson Y, Matenov A, Tschoke SK, et al. Impaired erythropoiesis after haemorrhagic shock in mice is associated with erythroid progenitor apoptosis in vivo. Acta Anaesthesiol Scand. 2008;52:605–613
  5. Jirtle RL, Skinner MK. Environmental epigenomics and disease susceptibility. Nat Rev Genet. 2007;8:253–262
  6. Lu SJ, Li F, Vida L, et al. CD34+ CD38− hematopoietic precursors derived from human enbryonic stem cells exhibit an embryonic gene expression pattern. Blood. 2004;103:4134–4141
  7. Georgantas RW, Tanadve V, Malehorn M, et al. Microarray and serial analysis of gene expression analyses identify known and novel transcripts overexpressed in hematopoietic stem cells. Cancer Res. 2004;64:4434–4441
  8. Gal H, Amariglio N, Trakhtenbrot L, et al. Gene expression profiles of AML derived stem cells; similarity to hematopoietic stem cells. Leukemia. 2006;20:2147–2154
  9. Wood BL, Arroz M, Barnett D, et al. 2006 Bethesda International Consensus recommendations on the immunophenotypic analysis of hematolymphoid neoplasia by flow cytometry: optimal reagents and reporting for the flow cytometric diagnosis of hematopoietic neoplasia. Cytometry B Clin Cytom. 2007;72(Suppl. 1):14–22
  10. Mutter GL, Zahrieh D, Liu C, et al. Comparison of frozen and RNALater solid tissue storage methods for use in RNA expression microarrays. BMC Genomics. 2004;5:88
  11. Iafrate AJ, Feuk L, Rivera MN, et al. Detection of large-scale variation in the human genome. Nat Genet. 2004;36:949–951
  12. Sebat J, Lakshmi B, Troge J, et al. Large-scale copy number polymorphism in the human genome. Science. 2004;305:525–528
  13. Bruder CE, Piotrowski A, Gijsbers AA, et al. Phenotypically concordant and discordant monozygotic twins display different DNA copy-number-variation profiles. Am J Hum Genet. 2008;82:763–771
  14. Salipante SJ, Horwitz MS. A phylogenetic approach to mapping cell fate. Curr Top Dev Biol. 2007;79:157–184
  15. Nilsson-Ehle H, Swolin B, Westin J. Bone marrow progenitor cell growth and karyotype changes in healthy 88-year-old subjects. Eur J Haematol. 1995;55:14–18
  16. Rossi DJ, Bryder D, Seita J, et al. Deficiencies in DNA damage repair limit the function of haematopoietic stem cells with age. Nature. 2007;447:725–729
  17. Flores M, Morales L, Gonzaga-Jauregui C, et al. Recurrent DNA inversion rearrangements in the human genome. Proc Natl Acad Sci U S A. 2007;104:6099–6106
  18. Cotton RG, Auerbach AD, Axton M, et al. GENETICS. The Human Variome Project. Science. 2008;322:861–862
  19. Spivakov M, Fisher AG. Epigenetic signatures of stem-cell identity. Nat Rev Genet. 2007;8:263–271
  20. Cedar H, Bergman Y. Linking DNA methylation and histone modification: patterns and paradigms. Nat Rev Genet. 2009;
  21. Probst AV, Dunleavy E, Almouzni G. Epigenetic inheritance during the cell cycle. Nat Rev Mol Cell Biol. 2009;10:192–206
  22. Klose RJ, Zhang Y. Regulation of histone methylation by demethylimination and demethylation. Nat Rev Mol Cell Biol. 2007;8:307–318
  23. Misteli T, Soutoglou E. The emerging role of nuclear architecture in DNA repair and genome maintenance. Nat Rev Mol Cell Biol. 2009;10:243–254
  24. Jiang C, Pugh BF. Nucleosome positioning and gene regulation: advances through genomics. Nat Rev Genet. 2009;10:161–172
  25. Henikoff S. Nucleosome destabilization in the epigenetic regulation of gene expression. Nat Rev Genet. 2008;9:15–26
  26. Shi Y. Histone lysine demethylases: emerging roles in development, physiology and disease. Nat Rev Genet. 2007;8:829–833
  27. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006;5:769–784
  28. Darnell JE. Transcription factors as targets for cancer therapy. Nat Rev Cancer. 2002;2:740–749
  29. Wei CL, Wu Q, Vega VB, et al. A global map of p53 transcription-factor binding sites in the human genome. Cell. 2006;124:207–219
  30. Cawley S, Bekiranov S, Ng HH, et al. Unbiased mapping of transcription factor binding sites along human chromosomes 21 and 22 points to widespread regulation of noncoding RNAs. Cell. 2004;116:499–509
  31. Payne KJ, Huang G, Sahakian E, et al. Ikaros isoform x is selectively expressed in myeloid differentiation. J Immunol. 2003;170:3091–3098
  32. Georgopoulos K. Haematopoietic cell-fate decisions, chromatin regulation and ikaros. Nat Rev Immunol. 2002;2:162–174
  33. Erdmann VA, Szymanski M, Hochberg A, et al. Collection of mRNA-like non-coding RNAs. Nucleic Acids Res. 1999;27:192–195
  34. Dermitzakis ET, Reymond A, Scamuffa N, et al. Evolutionary discrimination of mammalian conserved non-genic sequences (CNGs). Science. 2003;302:1033–1035
  35. Reinhart BJ, Slack FJ, Basson M, et al. The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature. 2000;403:901–906
  36. Chen CZ, Li L, Lodish HF, et al. MicroRNAs modulate hematopoietic lineage differentiation. Science. 2004;303:83–86
  37. Lim LP, Lau NC, Garrett-Engele P, et al. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature. 2005;433:769–773
  38. Lai EC. Micro RNAs are complementary to 3' UTR sequence motifs that mediate negative post-transcriptional regulation. Nat Genet. 2002;30:363–364
  39. Georgantas RW, Hildreth R, Morisot S, et al. CD34+ hematopoietic stem-progenitor cell microRNA expression and function: a circuit diagram of differentiation control. Proc Natl Acad Sci U S A. 2007;104:2750–2755
  40. Wang X, Arai S, Song X, et al. Induced ncRNAs allosterically modify RNA-binding proteins in cis to inhibit transcription. Nature. 2008;454:126–130
  41. Pieroni E, de la Fuente van Bentem , Mancosu G, et al. Protein networking: insights into global functional organization of proteomes. Proteomics. 2008;8:799–816
  42. Blom N, Sicheritz-Ponten T, Gupta R, et al. Prediction of post-translational glycosylation and phosphorylation of proteins from the amino acid sequence. Proteomics. 2004;4:1633–1649
  43. Lin CY, Chin CH, Wu HH, et al. Hubba: hub objects analyzer–a framework of interactome hubs identification for network biology. Nucleic Acids Res. 2008;36:W438–W443
  44. Sanguinetti G, Noirel J, Wright PC. MMG: a probabilistic tool to identify submodules of metabolic pathways. Bioinformatics. 2008;24:1078–1084
  45. Margolin AA, Wang K, Lim WK, et al. Reverse engineering cellular networks. Nat Protoc. 2006;1:662–671
  46. Vakhrushev SY, Dadimov D, Peter-Katalinic J. Software platform for high-throughput glycomics. Anal Chem. 2009;
  47. Hergenrother PJ. Obtaining and screening compound collections: a user's guide and a call to chemists. Curr Opin Chem Biol. 2006;10:213–218
  48. Rossi D, Rasi S, Franceschetti S, et al. Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21. Leukemia. 2009;
  49. Amsen D, Antov A, Flavell RA. The different faces of Notch in T-helper-cell differentiation. Nat Rev Immunol. 2009;9:116–124
  50. Allen JA, Halverson-Tamboli RA, Rasenick MM. Lipid raft microdomains and neurotransmitter signalling. Nat Rev Neurosci. 2007;8:128–140
  51. Bray SJ. Notch signalling: a simple pathway becomes complex. Nat Rev Mol Cell Biol. 2006;7:678–689
  52. Guo W, Giancotti FG. Integrin signalling during tumour progression. Nat Rev Mol Cell Biol. 2004;5:816–826
  53. Kholodenko BN. Cell-signalling dynamics in time and space. Nat Rev Mol Cell Biol. 2006;7:165–176
  54. McKay MM, Morrison DK. Integrating signals from RTKs to ERK/MAPK. Oncogene. 2007;26:3113–3121
  55. Wood BL. Ten-color immunophenotyping of hematopoietic cells. Curr Protoc Cytom. 2005;Chapter 6:Unit6.21
  56. Massie C, Mills IG. The developing role of receptors and adaptors. Nat Rev Cancer. 2006;6:403–409
  57. Stirewalt DL, Radich JP. The role of FLT3 in haematopoietic malignancies. Nat Rev Cancer. 2003;3:650–665
  58. Robb L. Cytokine receptors and hematopoietic differentiation. Oncogene. 2007;26:6715–6723
  59. Hamilton JA. Colony-stimulating factors in inflammation and autoimmunity. Nat Rev Immunol. 2008;8:533–544
  60. Fischer EH, Charbonneau H, Tonks NK. Protein tyrosine phosphatases: a diverse family of intracellular and transmembrane enzymes. Science. 1991;253:401–406
  61. Ostman A, Hellberg C, Bohmer FD. Protein-tyrosine phosphatases and cancer. Nat Rev Cancer. 2006;6:307–320
  62. Schmierer B, Hill CS. TGFbeta-SMAD signal transduction: molecular specificity and functional flexibility. Nat Rev Mol Cell Biol. 2007;8:970–982
  63. Aggarwal BB. Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol. 2003;3:745–756
  64. Croft M. The role of TNF superfamily members in T-cell function and diseases. Nat Rev Immunol. 2009;9:271–285
  65. D'Souza B, Miyamoto A, Weinmaster G. The many facets of Notch ligands. Oncogene. 2008;27:5148–5167
  66. Staal FJ, Luis TC, Tiemessen MM. WNT signalling in the immune system: WNT is spreading its wings. Nat Rev Immunol. 2008;8:581–593
  67. Homey B, Muller A, Zlotnik A. Chemokines: agents for the immunotherapy of cancer?. Nat Rev Immunol. 2002;2:175–184
  68. Dorsam RT, Gutkind JS. G-protein-coupled receptors and cancer. Nat Rev Cancer. 2007;7:79–94
  69. Medzhitov R. Toll-like receptors and innate immunity. Nat Rev Immunol. 2001;1:135–145
  70. Turner M, Billadeau DD. VAV proteins as signal integrators for multi-subunit immune-recognition receptors. Nat Rev Immunol. 2002;2:476–486
  71. Agnes F, Shamoon B, Dina C, et al. Genomic structure of the downstream part of the human FLT3 gene: exon/intron structure conservation among genes encoding receptor tyrosine kinases (RTK) of subclass III. Gene. 1994;145:283–288
  72. Robinson DR, Wu YM, Lin SF. The protein tyrosine kinase family of the human genome. Oncogene. 2000;19:5548–5557
  73. Li E, Hristova K. Role of receptor tyrosine kinase transmembrane domains in cell signaling and human pathologies. Biochemistry. 2006;45:6241–6251
  74. Yu X, Zou J, Ye Z, et al. Notch signaling activation in human embryonic stem cells is required for embryonic, but not trophoblastic, lineage commitment. Cell Stem Cell. 2008;2:461–471
  75. Maillard I, Koch U, Dumortier A, et al. Canonical notch signaling is dispensable for the maintenance of adult hematopoietic stem cells. Cell Stem Cell. 2008;2:356–366
  76. Delaney C, Varnum-Finney B, Aoyama K, et al. Dose-dependent effects of the Notch ligand Delta1 on ex vivo differentiation and in vivo marrow repopulating ability of cord blood cells.. Blood. 2005;106:2693–2699
  77. Hinds DA, Kloek AP, Jen M, et al. Common deletions and SNPs are in linkage disequilibrium in the human genome. Nat Genet. 2006;38:82–85
  78. Syvanen AC. Toward genome-wide SNP genotyping. Nat Genet. 2005;37(Suppl.):S5–10
  79. Altug-Teber O, Dufke A, Poths S, et al. A rapid microarray based whole genome analysis for detection of uniparental disomy. Hum Mutat. 2005;26:153–159
  80. Green RE, Krause J, Ptak SE, et al. Analysis of one million base pairs of Neanderthal DNA. Nature. 2006;444:330–336
  81. Ley TJ, Mardis ER, Ding L, et al. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature. 2008;456:66–72
  82. Sultan M, Schulz MH, Richard H, et al. A global view of gene activity and alternative splicing by deep sequencing of the human transcriptome. Science. 2008;321:956–960
  83. McCarroll SA, Kuruvilla FG, Korn JM, et al. Integrated detection and population-genetic analysis of SNPs and copy number variation. Nat Genet. 2008;40:1166–1174
  84. Neil H, Malabat C, d'Aubenton-Carafa Y, et al. Widespread bidirectional promoters are the major source of cryptic transcripts in yeast. Nature. 2009;457:1038–1042
  85. Allen RC, Zoghbi HY, Moseley AB, et al. Methylation of HpaII and HhaI sites near the polymorphic CAG repeat in the human androgen-receptor gene correlates with X chromosome inactivation. Am J Hum Genet. 1992;51:1229–1239
  86. Felgner J, Heidorn K, Korbacher D, et al. Cell lineage specificity in G-CSF receptor gene methylation. Leukemia. 1999;13:530–534
  87. Herman JG, Graff JR, Myohanen S, et al. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A. 1996;93:9821–9826
  88. Hatada I, Fukasawa M, Kimura M, et al. Genome-wide profiling of promoter methylation in human. Oncogene. 2006;25:3059–3064
  89. Uchida T, Ohashi H, Aoki E, et al. Clonality analysis by methylation-specific PCR for the human androgen-receptor gene (HUMARA-MSP). Leukemia. 2000;14:207–212
  90. Massie CE, Mills IG. Chromatin immunoprecipitation (ChIP) methodology and readouts. Methods Mol Biol. 2009;505:123–137
  91. Yoder SJ, Enkemann SA. ChIP-on-Chip Analysis methods for Affymetrix Tiling Arrays. Methods Mol Biol. 2009;523:367–381
  92. Lockhart DJ, Dong H, Byrne MC, et al. Expression monitoring by hybridization to high-density oligonucleotide arrays. Nat Biotechnol. 1996;14:1675–1680
  93. Schena M, Shalon D, Davis RW, et al. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science. 1995;270:467–470
  94. Golub TR, Slonim DK, Tamayo P, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science. 1999;286:531–537
  95. Vardhanabhuti S, Blakemore SJ, Clark SM, et al. A comparison of statistical tests for detecting differential expression using Affymetrix oligonucleotide microarrays. OMICS. 2006;10:555–566
  96. Garzon R, Volinia S, Liu CG, et al. MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood. 2008;111:3183–3189
  97. Johnson JM, Castle J, Garrett-Engele P, et al. Genome-wide survey of human alternative pre-mRNA splicing with exon junction microarrays. Science. 2003;302:2141–2144
  98. Purdom E, Simpson KM, Robinson MD, et al. FIRMA: a method for detection of alternative splicing from exon array data. Bioinformatics. 2008;24:1707–1714
  99. O'Farrell PH. High resolution two-dimensional electrophoresis of proteins. J Biol Chem. 1975;250:4007–4021
  100. Macek B, Mann M, Olsen JV. Global and site-specific quantitative phosphoproteomics: principles and applications. Annu Rev Pharmacol Toxicol. 2009;49:199–221
  101. Jahn O, Hesse D, Reinelt M, et al. Technical innovations for the automated identification of gel-separated proteins by MALDI-TOF mass spectrometry. Anal Bioanal Chem. 2006;386:92–103
  102. Shadforth I, Bessant C. Genome annotating proteomics pipelines: available tools. Expert Rev Proteomics. 2006;3:621–629
  103. Favre-Kontula L, Sattonnet-Roche P, Magnenat E, et al. Detection and identification of plasma proteins that bind GlialCAM using ProteinChip arrays, SELDI-TOF MS, and nano-LC MS/MS. Proteomics. 2008;8:378–388
  104. Downard KM. Ions of the interactome: the role of MS in the study of protein interactions in proteomics and structural biology. Proteomics. 2006;6:5374–5384
  105. Irizarry RA, Hobbs B, Collin F, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 2003;4:249–264
  106. Xu XL, Olson JM, Zhao LP. A regression-based method to identify differentially expressed genes in microarray time course studies and its application in an inducible Huntington's disease transgenic model. Hum Mol Genet. 2002;11:1977–1985
  107. Forsberg EC, Bhattacharya D, Weissman IL. Hematopoietic stem cells: expression profiling and beyond. Stem Cell Rev. 2006;2:23–30
  108. Rossi DJ, Jamieson CH, Weissman IL. Stems cells and the pathways to aging and cancer. Cell. 2008;132:681–696
  109. Sharkis SJ, Collector MI, Barber JP, et al. Phenotypic and functional characterization of the hematopoietic stem cell. Stem Cells. 1997;15(Suppl. 1):41–44
  110. Ivanova NB, Dimos JT, Schaniel C, et al. A stem cell molecular signature. Science. 2002;298:601–604
  111. Ramalho-Santos M, Yoon S, Matsuzaki Y, et al. “Stemness”: transcriptional profiling of embryonic and adult stem cells. Science. 2002;298:597–600
  112. Evsikov AV, Solter D. Comment on “Stemness: transcriptional profiling of embryonic and adult stem cells” and “a stem cell molecular signature”. Science. 2003;302:393
  113. Fortunel NO, Otu HH, Ng HH, et al. Comment on “Stemness: transcriptional profiling of embryonic and adult stem cells” and “a stem cell molecular signature”. Science. 2003;302:393
  114. Ivanova NB, Dimos JT, Schaniel C, et al. Response to Comments on “ Stemness: Transcriptional Profiling of Embryonic and Adult Stem Cells” and “A Stem Cell Molecular Signature”. Science. 2003;302:393d
  115. Forsberg EC, Prohaska SS, Katzman S, et al. Differential expression of novel potential regulators in hematopoietic stem cells. PLoS Genet. 2005;1:e28
  116. Blobel GA. CREB-binding protein and p300: molecular integrators of hematopoietic transcription. Blood. 2000;95:745–755
  117. Eckner R. p300 and CBP as transcriptional regulators and targets of oncogenic events. Biol Chem. 1996;377:685–688
  118. Kasper LH, Boussouar F, Ney PA, et al. A transcription-factor-binding surface of coactivator p300 is required for haematopoiesis. Nature. 2002;419:738–743
  119. Kung AL, Rebel VI, Bronson RT, et al. Gene dose-dependent control of hematopoiesis and hematologic tumor suppression by CBP. Genes Dev. 2000;14:272–277
  120. Rebel VI, Kung AL, Tanner EA, et al. Distinct roles for CREB-binding protein and p300 in hematopoietic stem cell self-renewal. Proc Natl Acad Sci U S A. 2002;99:14789–14794
  121. Zhang P, Zhang X, Iwama A, et al. PU.1 inhibits GATA-1 function and erythroid differentiation by blocking GATA-1 DNA binding. Blood. 2000;96:2641–2648
  122. Zhang P, Behre G, Pan J, et al. Negative cross-talk between hematopoietic regulators: GATA proteins repress PU.1. Proc Natl Acad Sci U S A. 1999;96:8705–8710
  123. Weisel KC, Yildirim S, Schweikle E, et al. Regulation of FLT3 and its ligand in normal hematopoietic progenitor cells. Ann Hematol. 2009;88:203–211
  124. Majka M, Janowska-Wieczorek A, Ratajczak J, et al. Numerous growth factors, cytokines, and chemokines are secreted by human CD34(+) cells, myeloblasts, erythroblasts, and megakaryoblasts and regulate normal hematopoiesis in an autocrine/paracrine manner. Blood. 2001;97:3075–3085
  125. Amenomori T, Tomonaga M, Jinnai I, et al. Cytogenetic and cytochemical studies on progenitor cells of primary acquired sideroblastic anemia (PASA): involvement of multipotent myeloid stem cells in PASA clone and mosaicism with normal clone. Blood. 1987;70:1367–1372
  126. Linton PJ, Dorshkind K. Age-related changes in lymphocyte development and function. Nat Immunol. 2004;5:133–139
  127. Clot J, Charmasson E, Brochier J. Age-dependent changes of human blood lymphocyte subpopulations. Clin Exp Immunol. 1978;32:346–351
  128. Hong MS, Dan JM, Choi JY, et al. Age-associated changes in the frequency of naive, memory and effector CD8+ T cells. Mech Ageing Dev. 2004;125:615–618
  129. Lucivero G, Surico G, Mazzini G, et al. Age-related changes in the proliferative kinetics of phytohemagglutinin-stimulated lymphocytes. Analysis by uptake of tritiated precursors of DNA, RNA and proteins, and by flow cytometry. Mech Ageing Dev. 1988;43:259–267
  130. Chatta GS, Andrews RG, Rodger E, et al. Hematopoietic progenitors and aging: alterations in granulocytic precursors and responsiveness to recombinant human G-CSF, GM-CSF, and IL-3. J Gerontol. 1993;48:M207–M212
  131. NCI . SEER cancer statistics review 1975–2003. National Cancer Institute; 2004;1-31-2007. Ref Type: Electronic Citation
  132. Nijnik A, Woodbine L, Marchetti C, et al. DNA repair is limiting for haematopoietic stem cells during ageing. Nature. 2007;447:686–690
  133. Janzen V, Forkert R, Fleming HE, et al. Stem-cell ageing modified by the cyclin-dependent kinase inhibitor p16INK4a. Nature. 2006;443:421–426
  134. Liang Y, Van Zant G, Szilvassy SJ. Effects of aging on the homing and engraftment of murine hematopoietic stem and progenitor cells. Blood. 2005;106:1479–1487
  135. Chambers SM, Shaw CA, Gatza C, et al. Aging hematopoietic stem cells decline in function and exhibit epigenetic dysregulation. PLoS Biol. 2007;5:e201
  136. Kelly LM, Liu Q, Kutok JL, et al. FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model. Blood. 2002;99:310–318
  137. Kelly LM, Kutok JL, Williams IR, et al. PML/RARalpha and FLT3-ITD induce an APL-like disease in a mouse model. Proc Natl Acad Sci U S A. 2002;99:8283–8288
  138. Huntly BJ, Gilliland DG. Leukaemia stem cells and the evolution of cancer-stem-cell research. Nat Rev Cancer. 2005;5:311–321
  139. Bos JL, Fearon ER, Hamilton SR, et al. Prevalence of ras gene mutations in human colorectal cancers. Nature. 1987;327:293–297
  140. Yu CE, Oshima J, Fu YH, et al. Positional cloning of the Werner's syndrome gene. Science. 1996;272:258–262
  141. Pennisi E. Premature aging gene discovered. Science. 1996;272:193–194
  142. Kudlow BA, Kennedy BK, Monnat RJ. Werner and Hutchinson-Gilford progeria syndromes: mechanistic basis of human progeroid diseases. Nat Rev Mol Cell Biol. 2007;8:394–404
  143. Matsumoto T, Shimamoto A, Goto M, et al. Impaired nuclear localization of defective DNA helicases in Werner's syndrome. Nat Genet. 1997;16:335–336
  144. Kyng KJ, May A, Kolvraa S, et al. Gene expression profiling in Werner syndrome closely resembles that of normal aging. Proc Natl Acad Sci U S A. 2003;100:12259–12264
  145. Castro E, Ogburn CE, Hunt KE, et al. Polymorphisms at the Werner locus: I. Newly identified polymorphisms, ethnic variability of 1367Cys/Arg, and its stability in a population of Finnish centenarians. Am J Med Genet. 1999;82:399–403
  146. Agrelo R, Cheng WH, Setien F, et al. Epigenetic inactivation of the premature aging Werner syndrome gene in human cancer. Proc Natl Acad Sci U S A. 2006;103:8822–8827
  147. Stirewalt DL, Choi YE, Sharpless NE, et al. Decreased IRF8 expression found in aging hematopoietic progenitor/stem cells. Leukemia. 2009;23:391–393
  148. Holtschke T, Lohler J, Kanno Y, et al. Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene. Cell. 1996;87:307–317
  149. Schwieger M, Lohler J, Friel J, et al. AML1-ETO inhibits maturation of multiple lymphohematopoietic lineages and induces myeloblast transformation in synergy with ICSBP deficiency. J Exp Med. 2002;196:1227–1240
  150. Schmidt M, Hochhaus A, Nitsche A, et al. Expression of nuclear transcription factor interferon consensus sequence binding protein in chronic myeloid leukemia correlates with pretreatment risk features and cytogenetic response to interferon-alpha. Blood. 2001;97:3648–3650
  151. Diaz-Blanco E, Bruns I, Neumann F, et al. Molecular signature of CD34(+) hematopoietic stem and progenitor cells of patients with CML in chronic phase. Leukemia. 2007;21:494–504
  152. Schmidt M, Nagel S, Proba J, et al. Lack of interferon consensus sequence binding protein (ICSBP) transcripts in human myeloid leukemias. Blood. 1998;91:22–29
  153. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature. 1993;366:704–707
  154. Haidar MA, Cao XB, Manshouri T, et al. p16INK4A and p15INK4B gene deletions in primary leukemias. Blood. 1995;86:311–315
  155. Sulong S, Moorman AV, Irving JA, et al. A comprehensive analysis of the CDKN2A gene in childhood acute lymphoblastic leukemia reveals genomic deletion, copy number neutral loss of heterozygosity, and association with specific cytogenetic subgroups. Blood. 2009;113:100–107
  156. Molofsky AV, Slutsky SG, Joseph NM, et al. Increasing p16INK4a expression decreases forebrain progenitors and neurogenesis during ageing. Nature. 2006;443:448–452
  157. Krishnamurthy J, Ramsey MR, Ligon KL, et al. p16INK4a induces an age-dependent decline in islet regenerative potential. Nature. 2006;443:453–457
  158. Stirewalt DL, Kopecky KJ, Meshinchi S, et al. FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. Blood. 2001;97:3589–3595
  159. Dumble M, Moore L, Chambers SM, et al. The impact of altered p53 dosage on hematopoietic stem cell dynamics during aging. Blood. 2007;109:1736–1742
  160. Sterkers Y, Preudhomme C, Lai JL, et al. Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion. Blood. 1998;91:616–622
  161. Venkatachalam S, Shi YP, Jones SN, et al. Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation. EMBO J. 1998;17:4657–4667
  162. Tyner SD, Venkatachalam S, Choi J, et al. p53 mutant mice that display early ageing-associated phenotypes. Nature. 2002;415:45–53
  163. Bojesen SE, Nordestgaard BG. The common germline Arg72Pro polymorphism of p53 and increased longevity in humans. Cell Cycle. 2008;7:158–163
  164. van Heemst D, Mooijaart SP, Beekman M, et al. Variation in the human TP53 gene affects old age survival and cancer mortality. Exp Gerontol. 2005;40:11–15
  165. Sharpless NE, DePinho RA. How stem cells age and why this makes us grow old. Nat Rev Mol Cell Biol. 2007;8:703–713
  166. Finkel T, Serrano M, Blasco MA. The common biology of cancer and ageing. Nature. 2007;448:767–774
  167. Rossi DJ, Bryder D, Zahn JM, et al. Cell intrinsic alterations underlie hematopoietic stem cell aging. Proc Natl Acad Sci U S A. 2005;102:9194–9199
  168. Prall WC, Czibere A, Jager M, et al. Age-related transcription levels of KU70, MGST1 and BIK in CD34+ hematopoietic stem and progenitor cells. Mech Ageing Dev. 2007;128:503–510
  169. Nilsson SK, Johnston HM, Coverdale JA. Spatial localization of transplanted hemopoietic stem cells: inferences for the localization of stem cell niches. Blood. 2001;97:2293–2299
  170. Adams GB, Chabner KT, Alley IR, et al. Stem cell engraftment at the endosteal niche is specified by the calcium-sensing receptor. Nature. 2006;439:599–603
  171. Ilnytskyy Y, Zemp FJ, Koturbash I, et al. Altered microRNA expression patterns in irradiated hematopoietic tissues suggest a sex-specific protective mechanism. Biochem Biophys Res Commun. 2008;377:41–45
  172. Dressman HK, Muramoto GG, Chao NJ, et al. Gene expression signatures that predict radiation exposure in mice and humans. PLoS Med. 2007;4:e106
  173. Lu X, de la Pena L, Barker C, et al. Radiation-induced changes in gene expression involve recruitment of existing messenger RNAs to and away from polysomes. Cancer Res. 2006;66:1052–1061
  174. Bender MA, Gooch PC. Persistent chromosome aberrations in irradiated human subjects. Radiat Res. 1962;16:44–53
  175. Amundson SA, Grace MB, McLeland CB, et al. Human in vivo radiation-induced biomarkers: gene expression changes in radiotherapy patients. Cancer Res. 2004;64:6368–6371
  176. Mori M, Benotmane MA, Vanhove D, et al. Effect of ionizing radiation on gene expression in CD4+ T lymphocytes and in Jurkat cells: unraveling novel pathways in radiation response. Cell Mol Life Sci. 2004;61:1955–1964
  177. Ford JM. Regulation of DNA damage recognition and nucleotide excision repair: another role for p53. Mutat Res. 2005;577:195–202
  178. Pukkala E, Auvinen A, Wahlberg G. Incidence of cancer among Finnish airline cabin attendants, 1967–92. BMJ. 1995;311:649–652
  179. Nicholas JS, Butler GC, Davis S, et al. Stable chromosome aberrations and ionizing radiation in airline pilots. Aviat Space Environ Med. 2003;74:953–956
  180. Wang Z, Neuberg D, Su L, et al. Prospective study of metal fume-induced responses of global gene expression profiling in whole blood. Inhal Toxicol. 2008;20:1233–1244
  181. Schmidt WM, Spiel AO, Jilma B, et al. In vivo profile of the human leukocyte microRNA response to endotoxemia. Biochem Biophys Res Commun. 2009;380:437–441
  182. Suzuki T, Hashimoto S, Toyoda N, et al. Comprehensive gene expression profile of LPS-stimulated human monocytes by SAGE. Blood. 2000;96:2584–2591
  183. Lampe JW, Stepaniants SB, Mao M, et al. Signatures of environmental exposures using peripheral leukocyte gene expression: tobacco smoke. Cancer Epidemiol Biomarkers Prev. 2004;13:445–453
  184. van Leeuwen DM, van Agen E, Gottschalk RW, et al. Cigarette smoke-induced differential gene expression in blood cells from monozygotic twin pairs. Carcinogenesis. 2007;28:691–697
  185. Bijl M, Horst G, Limburg PC, et al. Effects of smoking on activation markers, Fas expression and apoptosis of peripheral blood lymphocytes. Eur J Clin Invest. 2001;31:550–553
  186. van Eeden SF, Hogg JC. The response of human bone marrow to chronic cigarette smoking. Eur Respir J. 2000;15:915–921
  187. Vijayalaxmi , Evans HJ. In vivo and in vitro effects of cigarette smoke on chromosomal damage and sister-chromatid exchange in human peripheral blood lymphocytes. Mutat Res. 1982;92:321–332
  188. Bridges RB, Wyatt RJ, Rehm SR. Effects of smoking on inflammatory mediators and their relationship to pulmonary dysfunction. Eur J Respir Dis Suppl. 1986;146:145–152
  189. Kaufman DW, Kelly JP, Rosenberg L, et al. Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA. 2002;287:337–344
  190. Vogel M, Pfeifer S, Schaub RT, et al. Decreased levels of dopamine D3 receptor mRNA in schizophrenic and bipolar patients. Neuropsychobiology. 2004;50:305–310
  191. Iga J, Ueno S, Yamauchi K, et al. Serotonin transporter mRNA expression in peripheral leukocytes of patients with major depression before and after treatment with paroxetine. Neurosci Lett. 2005;389:12–16
  192. Westermark B, Claesson-Welsh L, Heldin CH. Structural and functional aspects of platelet-derived growth factor and its receptors. Ciba Found Symp. 1990;150:6–14
  193. Bazan JF. Structural design and molecular evolution of a cytokine receptor superfamily. Proc Natl Acad Sci U S A. 1990;87:6934–6938
  194. Cannistra SA, Groshek P, Garlick R, et al. Regulation of surface expression of the granulocyte/macrophage colony-stimulating factor receptor in normal human myeloid cells. Proc Natl Acad Sci U S A. 1990;87:93–97
  195. Chiba S, Tojo A, Kitamura T, et al. Characterization and molecular features of the cell surface receptor for human granulocyte-macrophage colony-stimulating factor. Leukemia. 1990;4:29–36
  196. Bierie B, Moses HL. Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer. 2006;6:506–520
  197. Rizzo P, Osipo C, Foreman K, et al. Rational targeting of Notch signaling in cancer. Oncogene. 2008;27:5124–5131
  198. Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature. 2005;434:843–850
  199. Nusse R. Wnt signaling and stem cell control. Cell Res. 2008;18:523–527
  200. Huang HC, Klein PS. The Frizzled family: receptors for multiple signal transduction pathways. Genome Biol. 2004;5:234
  201. Bilic J, Huang YL, Davidson G, et al. Wnt induces LRP6 signalosomes and promotes dishevelled-dependent LRP6 phosphorylation. Science. 2007;316:1619–1622

PII: S1521-6926(09)00031-0

doi: 10.1016/j.beha.2009.05.005

Best Practice & Research Clinical Haematology
Volume 22, Issue 2 , Pages 249-269 , June 2009

Article Tools

* Image Usage & Resolution